Dr. Nathalie Adda named new chief medical officer at Enanta Pharmaceuticals
Adda will now be responsible for the company’s regulatory and clinical affairs. She brings more than 15 years of pharmaceutical industry experience to Enanta. She specializes in infectious diseases and has worked in all phases of global clinical development, research and commercialization.
Previously, Adda worked at Transgene SA as the chief medical officer, VP of clinical development, medical and regulatory affairs. She led the oncology and infectious disease programs beginning in 2012.
Between 2006 and 2012, she served as the senior medical director as well as the medical lead with the Incivek (telaprevir) Clinical Program with Vertex Pharmaceuticals Inc. While there, she created the phase 2 and 3 programs. She also led the company’s medical team through marketing registration and applications in Asia, Canada and the U.S.
“Nathalie is a welcome addition to our executive management team," President and CEO Dr. Jay R. Luly said. "Her clinical and regulatory expertise will be invaluable to us as we prepare to advance our internal virology and liver disease programs.”